Source comparison
BPC-157 Arthritis Research: Mechanism Comparison
Primary Pathway VEGF upregulation, angiogenesis promotion, NO modulation COX-1/COX-2 inhibition, prostaglandin suppression Glucocorticoid receptor activation, broad immune suppression BPC-157 operates through tissue repair pathways distinct from standard anti-
This comparison does not assign a generated winner or score.
- Primary Pathway
- VEGF upregulation, angiogenesis promotion, NO modulation
- COX-1/COX-2 inhibition, prostaglandin suppression
- Glucocorticoid receptor activation, broad immune suppression
- BPC-157 operates through tissue repair pathways distinct from standard anti-inflammatory drugs
- Effect on Collagen Synthesis
- Increases Type I collagen deposition, improves fiber alignment
- Neutral to mildly inhibitory at high doses
- Actively suppresses collagen synthesis and wound healing
- BPC-157 supports structural repair; corticosteroids impair it
- Cartilage Protection
- Reduces IL-6, TNF-alpha; preserves cartilage in arthritis models
- Symptom relief without cartilage-sparing effect in most studies
- Short-term inflammation control but accelerates cartilage degradation long-term
- BPC-157 shows cartilage preservation that NSAIDs and steroids don't replicate
- Vascular Effects
- Promotes microvascular repair, increases capillary density
- Can impair vascular healing, risk of GI ulceration
- Suppresses VEGF, impairs angiogenesis
- BPC-157 enhances tissue perfusion; corticosteroids reduce it
- Study Model Evidence
- Rodent arthritis models (adjuvant-induced, collagen-induced) with histological endpoints
- Extensive human clinical trial data for symptom management
- Human data for acute flare management, not chronic repair
- BPC-157 preclinical data robust but human trials limited; NSAIDs and steroids have decades of clinical use